# Baek‐Yeol Ryoo

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/baek-yeol-ryoo/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,902 |
| Field | Hepatocellular Carcinoma Treatment and Prognosis |
| h-index | 65 |
| i10-index | 251 |
| Last Known Institution | Ulsan College |
| OpenAlex ID | https://openalex.org/A5050625196 |
| ORCID iD | https://orcid.org/0000-0002-9052-833X |
| Works | 497 |

## Researcher papers

- [Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial](https://scholariq.org/papers/ramucirumab-versus-placebo-as-second-line-treatment-in-patients-with-advanced/)
- [Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study](https://scholariq.org/papers/atezolizumab-with-or-without-bevacizumab-in-unresectable-hepatocellular/)
- [Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-lenvatinib-plus-placebo-for-advanced/)
- [Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO](https://scholariq.org/papers/pan-asian-adapted-esmo-clinical-practice-guidelines-for-the-management-of-2/)
- [Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line](https://scholariq.org/papers/epithelial-to-mesenchymal-transition-derived-from-repeated-exposure-to-gefitinib/)
- [Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial](https://scholariq.org/papers/pembrolizumab-versus-placebo-as-second-line-therapy-in-patients-from-asia-with/)

## Researcher topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Ulsan College](https://scholariq.org/institutions/ulsan-college/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.